Abstract:Neuroinflammation is a key factor of the pathology of various neurological diseases (brain injury, depression, neurodegenerative diseases). It is a complex and orderly process that relies on various types of glial cells and peripheral immune cells. Inhibition of neuroinflammation can reduce the severity of neurological diseases. The initiation, progression, and termination of inflammation require gene activation, epigenetic modification, transcriptional translation, and post-translational regulation, all of which are tightly regulated by different enzymes. Epigenetics refers to the regulation of epigenetic gene expression by epigenetic changes (DNA methylation, histone modification, and non-coding RNAs such as miRNA) that are not dependent on changes in gene sequence and are heritable. Histone deacetylases (HDACs) are a group of important enzymes that regulate epigenetics. They can remove the acetyl group on the lysine ϵ-amino group of the target protein, thereby affecting gene transcription or altering protein activity. HDACs are involved in the regulation of immunity and inflammation. HDAC inhibitor (HDACi) has also become a new hotspot in the research of anti-inflammatory drugs. Therefore, the aim of the current review is to discuss and summarize the role and mechanism of different HDACs in neuroinflammation and the corresponding role of HDACi in neurological diseases, and to providing new ideas for future research on neuroinflammation-related diseases and drug development.

HDACi: molecular mechanisms and therapeutic implications in the innate immune system

Classical HDACs in the Regulation of Neuroinflammation.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

HDACs and their inhibitors in immunology: teaching anticancer drugs new tricks

New Development of HDAC Inhibitors As Anti-Cancer Agents

HDAC-targeting epigenetic modulators for cancer immunotherapy

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Strategies in Developing Promising Histone Deacetylase Inhibitors.

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Advances of histone deacetylases inhibitors as novel anti-cancer agents in clinical study

Histone deacetylases and their inhibitors in inflammatory diseases

[Research Progress of Histone Deacetylase Inhibitor Combined with Immune Checkpoint Inhibitor in the Treatment of Tumor].

Histone Deacetylases (HDACs) Roles in Inflammation-mediated Diseases; Current Knowledge

Targeting histone deacetylases for cancer therapy: Trends and challenges

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases

HDAC11: A novel target for improved cancer therapy